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Interaction mapping is a powerful strategy to elucidate the biological function of protein
assemblies and their regulators. Here, we report the generation of a quantitative interaction
network, directly linking 14 human proteins to the AAAþ ATPase p97, an essential
hexameric protein with multiple cellular functions. We show that the high-affinity interacting
protein ASPL efficiently promotes p97 hexamer disassembly, resulting in the formation of
stable p97:ASPL heterotetramers. High-resolution structural and biochemical studies indicate
that an extended UBX domain (eUBX) in ASPL is critical for p97 hexamer disassembly
and facilitates the assembly of p97:ASPL heterotetramers. This spontaneous process is
accompanied by a reorientation of the D2 ATPase domain in p97 and a loss of its activity.
Finally, we demonstrate that overproduction of ASPL disrupts p97 hexamer function in ERAD
and that engineered eUBX polypeptides can induce cell death, providing a rationale for
developing anti-cancer polypeptide inhibitors that may target p97 activity.
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M
ost biological processes are controlled by dynamic
protein–protein interactions (PPIs), which form
molecular networks of enormous complexity1,2.
Several methods for the identification and characterization of
PPIs have been developed, and some have been applied in
large-scale studies3–6. Among these, the yeast two-hybrid (Y2H)
system has been particularly attractive for PPI screening
because binary interactions can be systematically and rapidly
tested in an automated process at relatively low cost7,8. Y2H PPI
data, however, are qualitative and do not provide information
on interactions strength9, which is important for a better
understanding of the cellular organization of proteins and the
regulation of complex biological systems like signal transduction
or gene expression10.
Recently, luminescence-based PPI mapping technologies
such as LUMIER with BACON11,12 or DULIP13 have been
established, which provide quantitative information about the
association of proteins. The distinction between weak and strong
interactions allows now the generation of quantitative interaction
networks. This is very useful for the prioritization of PPIs
for focused functional validation and for the identification of
proteins that might be able to disrupt protein complexes14.
Through the generation of a comprehensive quantitative
chaperone interaction network, for example, the architecture of
cellular protein homoeostasis pathways was elucidated15.
The AAAþ ATPase p97, also known as VCP (valosin-
containing protein) in mammals or Cdc48 in yeast, is a
homohexameric ring-shaped molecular machine that together
with partner proteins controls a plethora of essential cellular
processes such as ubiquitin-dependent protein degradation16,
maintenance of quality control17 or homotypic membrane
fusion18. It comprises four domains: a flexible N-terminal
domain (N), two AAAþ ATPase domains (D1 and D2) and
an unstructured C-terminal tail19,20. p97 is an essential protein,
with orthologues in archaea and all eukaryotes. It is also
highly relevant to disease, as it is mutated in familial cases of
inclusion body myopathy associated with Paget disease of the
bone and frontotemporal dementia (IBMPFD) and in amyotrophic
lateral sclerosis21,22. There is increasing evidence that p97 is
critical for proliferation of cancer cells23. p97 hexamers, therefore,
are a target for cancer therapies. Small molecules inhibiting p97
ATPase activity have recently been identified24.
A large number of p97 interaction partners have been
identified with proteomics methods and biochemical assays25,26.
This includes 13 ubiquitin regulatory X (UBX) domain-
containing proteins that commonly interact with the conserved
N domain27. This domain is positioned at the periphery of p97
hexamers and acts as an allosteric regulator of ATPase activity28.
Partners binding to it with high affinity might control p97
function by influencing its ATPase activity29. Information about
the binding strengths of most known p97 interacting proteins is,
however, not available.
To identify high-affinity binders, we decided to generate
a quantitative p97 interaction map, involving automated
Y2H screening followed by systematic validation of identified
interactions in a dual luminescence-based co-immuno-
precipitation (DULIP) assay. We discovered 12 high-confidence
p97 interaction partners, four of which had been reported
previously, including the UBX domain-containing protein ASPL
(alveolar soft part sarcoma locus), which showed the highest
binding strength in DULIP assays. Biochemical and structural
studies revealed that a C-terminal fragment of ASPL is necessary
and sufficient for p97 binding. This fragment causes efficient p97
hexamer disassembly and spontaneous formation of a hetero-
tetrameric p97:ASPL protein complex. Strikingly, overproduction
of ASPL caused disruption of functional p97 hexamers in cell
models and blockage of ERAD. Finally, we showed that
engineered ASPL-derived polypeptides can potently inhibit
cell growth, suggesting that such molecules may be suitable as
anti-cancer treatments.
Results
Identification of p97 interacting proteins. We applied an
automated yeast two-hybrid (Y2H) system4 to identify p97
interaction partners. Eight MATa yeast strains producing
non-autoactivating p97 fragments (Supplementary Fig. 1a) were
pooled and mated on YPD agar plates withB16,000 MATa yeast
strains expressing human prey proteins. Interacting bait and prey
proteins were finally identified through growth assays on selective
agar plates. To increase our sampling the prey library was
screened four times. Then, potential PPIs were tested pair wise in
4–6 independent mating experiments. Only pairs tested positive
at least three times were considered as positive interactions. This
interaction mating approach revealed 14 unique p97 partner
proteins, 6 (B43%) of which have been reported previously
(Fig. 1a,b, and Supplementary Table 1).
We identified well-characterized p97 partner proteins such as
p47, NPL4 or ATXN3 (ref. 16) and largely uncharacterized
proteins such as UBXD4 (ref. 25). The majority of identified
proteins interact with the N-terminus of p97 (Supplementary
Table 1). This region contains the N domain, which has been
shown to be critical for recruiting many adaptor proteins30.
In our study, four UBX domain-containing proteins were
identified that interact with N-terminal p97 fragments,
confirming previously reported observations16. Overall, several
p97 interactors with a functional role in ubiquitin-mediated
protein degradation pathways were revealed (Supplementary
Fig. 1b), supporting previous observations that p97 and its
partners play a critical role in these processes30.
DULIP-based ranking of p97 interacting proteins. To validate
Y2H PPIs, a DULIP assay was applied, providing quantitative
interaction information13. We systematically examined the
interactions between protein-A-Renilla luciferase (PA-RL)-tagged
fusion proteins and firefly luciferase (FL)-tagged fusion proteins in
HEK293 cells. Through quantification of luciferase activities of
precipitated protein complexes, background-corrected normalized
interaction ratios (cNIRs) were calculated for all tested interactions
(Fig. 1c and Supplementary Fig. 1c,d). These ratios are an
indication of interaction strength, allowing the distinction of
potentially high from low affinity interactions13. We used a
stringent cNIR cutoff of 43 to define DULIP-positive PPIs13.
Under these conditions 12 out of 14 (86%) tested Y2H interactions
could be reproduced in DULIP assays with full-length p97 as a
bait. The cNIRs varied over a range ofB750-fold, suggesting that
proteins interact with p97 with very different binding strengths.
The cNIRs ranked the UBX domain-containing ASPL
(Supplementary Fig. 1d) as the strongest p97 binder.
To substantiate this result, we finally employed biolayer
interferometry (BLI)31 measurements to determine the binding
affinity between purified His-tagged full-length ASPL and p97
(Supplementary Fig. 1e,f). The interaction between the full-length
proteins was confirmed to be very strong with a dissociation
constant (KD) ofE2 nM (Supplementary Fig. 1f), supporting our
results with the DULIP assays (Fig. 1c and Supplementary
Fig. 1d). Therefore, we selected the interaction between ASPL
and p97 for more detailed characterization with biochemical and
structural methods.
ASPL binding to p97 involves an extended UBX domain. First,
we assessed whether ASPL and p97 form a protein complex under
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physiological conditions. We found that p97 was efficiently
co-immunoprecipitated by anti-ASPL antibodies from human
post-mortem brain protein extract, but not by control antibodies
or beads alone (Fig. 2a). This result was also confirmed when an
anti-p97 antibody was utilized for co-immunoprecipitation
(Supplementary Fig. 2a). Next, we defined the binding regions
that are critical for the interaction. We first generated deletion
fragments for ASPL and systematically investigated whether they
associate with full-length p97 in DULIP assays (Supplementary
Fig. 2b–c). As UBX domains in adaptor proteins have been shown
to be critical for their interaction with p97 (ref. 32), we assumed
this to be the case also for ASPL. Interestingly, cell-based PPI
mapping revealed that the conserved UBX domain of ASPL
(residues 377–462) alone does not interact with p97. However, an
extended UBX (eUBX) domain-containing fragment (residues
313–553)—termed ASPL-C—showed strong binding to p97
(Fig. 2b and Supplementary Fig. 2c), indicating that amino acid
residues located up- and downstream of the UBX domain are
b c
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Figure 1 | A quantitative p97 interaction network identifies ASPL as a strong binding partner of p97. (a) Schematic representation of the workflow for the
generation of a quantitative binary p97 PPI interaction network using sequential applications of automated yeast two-hybrid technology (Phase I) and DULIP
assays (Phase II). (b) Network graph of protein–protein interactions of p97 identified by automated Y2H assay. (c) Overlay of the DULIP assay data to the p97
Y2H network resulted in the generation of the quantitative binary interaction network for p97. In DULIP assays full-length p97 protein was utilized as bait.
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critical for the interaction with p97. This observation was
independently verified by co-immunoprecipitations of V5-tagged
truncated ASPL fragments and endogenous p97 from HEK293
cell extracts (Supplementary Fig. 3a).
Conversely, we also mapped the ASPL-binding region in p97
with DULIP assays (Supplementary Fig. 2d), revealing a relatively
weak interaction between full-length ASPL and the N domain of
p97 (aa 1–208). However, a stronger PPI was observed with the
N-terminal p97-ND1 fragment (residues 1–480), which includes
the N domain and the conserved D1 ATPase domain, indicating
that both domains are critical for strong ASPL binding.
The interaction between ASPL-C and p97-ND1 was then
examined with purified recombinant proteins using isothermal
titration calorimetry (ITC), revealing a very stable association of
these fragments in vitro (KDE0.2 nM; Supplementary Fig. 3b).
Previous investigations demonstrated that binding of
nucleotides such as ATP or ADP alters the conformation
of p97 hexamers33, suggesting that they might also influence
the interaction between ASPL and p97. GST pull-down assays
showed that ATP, ADP or AMP-PNP do not significantly
influence the binding of GST-ASPL-C to full-length p97
(Supplementary Fig. 3c), supporting the view that both proteins
form a very stable complex in vitro.
ASPL-C converts p97 hexamers into stable heterotetramers.
We next examined the interaction between ASPL-C and p97 by
blue native-PAGE (BN-PAGE), which allows the detection of
protein complexes under non-denaturing conditions. We observed
that p97 migrates at a molecular mass of B700 kDa (Fig. 2c),
confirming the formation of stable hexamers19. However, these
structures disappeared in the presence of increasing concentrations
of ASPL-C while two lower molecular weight protein bands
migrating at B230 and B480 kDa were detectable. This suggests
that ASPL-C binding promotes the conversion of p97 hexamers
into smaller p97:ASPL-C heterooligomers (Fig. 2c). Analysis by
mass spectrometry revealed that these protein bands contain both
p97 and ASPL-C polypeptides, supporting this hypothesis
(Supplementary Fig. 4a,b). In strong contrast, heterooligomeric
p97:ASPL-C protein complexes were not detectable when
samples were analysed by SDS–polyacrylamide gel electro-
phoresis (SDS–PAGE) (Supplementary Fig. 3d).
Next, we analysed the interaction between p97 hexamers and
ASPL-C by size-exclusion chromatography followed by static
light scattering (SEC-SLS). A prominent peak was revealed at
B230 kDa (Supplementary Fig. 4c), indicating the formation of
stable p97:ASPL-C heterotetramers from p97 homohexamers.
Finally, we studied the effect of ASPL-C on p97 hexamers with
negative-stain electron microscopy (EM). We observed typical
ring-shaped hexameric p97 particles with diameters of B14 nm
in the absence of ASPL-C (Fig. 2d), confirming previously
published results34. These structures, however, were not
detectable in the presence of ASPL-C, supporting the
observations that ASPL-C binding promotes p97 hexamer
disassembly (Fig. 2c and Supplementary Fig. 4c).
Structure of p97-ND1:ASPL-C heterotetramers. To examine the
molecular details of the interaction between p97 and ASPL, we
determined the crystal structure of an ADP-bound p97-ND1
fragment in complex with ASPL-C at 2.46Å resolution using
molecular replacement (Supplementary Table 2). Two molecules
each of p97-ND1 and ASPL-C were present in the asymmetric
unit of the crystal, forming a compact heterotetrameric
p97-ND1:ASPL-C protein complex (Fig. 3a). These results
confirm the observations by BN-PAGE (Fig. 2c) that ASPL-C
binding to p97 hexamers promotes the formation of stable
heterooligomers (Fig. 2c and Supplementary Fig. 4c).
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Figure 2 | ASPL-C converts p97 hexamers into stable p97:ASPL-C heterooligomers. (a) Co-immunoprecipitation of a p97:ASPL protein complex from
human brain homogenate using an anti-ASPL antibody. Anti-FLAG antibody and beads alone were used as negative controls. (b) Schematic representation
of fragments and full-length ASPL and p97. Conserved protein domains are depicted: ubiquitin-like domain (UBL); ubiquitin regulatory-X domain (UBX);
N-terminal protein binding domains (Na and Nb); ATPase domains (D1 and D2). (c) Blue-native gel stained with Coomassie Brilliant Blue, demonstrating the
remodelling of p97 hexamers by ASPL-C in a concentration-dependent manner. p97 (10mg) and ASPL-C (0.3, 0.6, 1.8, 3, 6 and 12 mg) were briefly mixed
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Assembly of the heterotetrameric p97-ND1:ASPL-C complex
buries a total of 5,300Å2 of solvent-accessible surface in both
proteins. Two heterodimeric p97-ND1:ASPL-C units were
found to be interlocked with each other, forming a central cavity
with a diameter of B17Å (Fig. 3a, Supplementary Movie 1).
In each heterodimer, the N and D1 domains of p97-ND1 bind to
ASPL-C primarily via polar interactions, burying an extensive
interface area of 2,300Å2. Two such heterodimeric units are
assembled via a second interaction interface of 700Å2 including
many polar and van der Waals interactions. The overall structure
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of the p97-ND1 fragment in the heterotetramer shows high
similarity to p97-ND1 in p47 bound hexamers (r.m.s.d.¼ 0.95Å;
Supplementary Fig. 5a).
The conserved UBX-domain core (residues 390–466) in ASPL-C,
which forms a b-grasp fold27, is also similar to previously reported
structures of UBX domains in other p97-binding proteins
such as p47 (r.m.s.d.¼ 1.7Å), FAF1 (r.m.s.d.¼ 1.6Å) and Npl4
(r.m.s.d.¼ 2.2Å) (Supplementary Fig. 5b). However, we found that
the N- and C-terminal regions of the UBX domain in ASPL-C
contain unique structural extensions, which were not observed in
previously reported UBX-domain-containing proteins (Fig. 3b,c).
We termed this region eUBX. It comprises the canonical UBX
domain, three N-terminal extensions, b0, a 1, and a0 and two
C-terminal extensions, a3 and a4, which make extensive contact
with the b-grasp fold (Fig. 3c).
ASPL-C binding to p97-ND1 involves an a-helical lariat. In the
crystal structure, we observed that the association with p97-ND1
involves an a-helical lariat in ASPL-C (Fig. 3b–d). It consists of
two long helices a 1 and a0 and a long loop which are inserted
between b0 and b1 in the eUBX domain (Fig. 3b). Strikingly, the
a-helical lariat wraps around almost the entire Na subdomain of
p97, suggesting that it is critical for the conversion of hexamers
into heterotetramers (Fig. 3d). This assumption is supported by a
superimposition of the structure of ASPL-C in p97-ND1 het-
erotetramers onto the structure of previously reported p97-ND1
homohexamers (Fig. 5c and Supplementary Fig. 5c). It shows that
the a-helical lariat directly targets the D1:D1 interprotomer
interface in p97 hexamers, a region critical for hexamer stabi-
lity35, suggesting that it might play an important role in the
dissociation of p97 homohexamers.
Mutations in ASPL-C suppress p97 hexamer disassembly. To
investigate whether point mutations in the UBX domain or the
a-helical lariat influence ASPL-mediated p97 hexamer
disassembly, we generated the mutants D351A and PP437-438AA
and examined whether these ASPL-C variants can promote p97
hexamer dissociation. The conserved amino acid Asp351 was
chosen for mutagenesis because it is located in the a-helical lariat
(Supplementary Fig. 6a,b). Its exchange with Ala was expected to
reduce the binding of the lariat to p97 hexamers. Pro437 and
Pro438 locate in the canonical UBX domain of ASPL. They form a
conserved cis-Pro touch-turn structure (Supplementary Fig. 6c,d),
which docks to a hydrophobic pocket in p97, suggesting that it is
critical for the association of ASPL-C with p97.
Next, we examined whether wild-type (wt) ASPL-C and its
mutant variants D351A and PP437-438AA can promote p97
hexamer disassembly. Purified recombinant proteins were
incubated with p97 hexamers; the spontaneous formation of
putative heterooligomers was analysed by BN-PAGE and
immunoblotting (IB). In contrast to wt ASPL-C, the mutants
D351A and PP437-438AA showed a reduced ability to disassemble
p97 hexamers in vitro (Fig. 3e and Supplementary Fig. 6e),
indicating that both the a-helical lariat and the cis-Pro touch-turn
structure in ASPL-C are critical for hexamer dissociation.
ASPL binding inhibits p97 ATPase activity. To investigate
whether ASPL-mediated remodelling of p97 hexamers influences
ATP hydrolysis, we performed ATPase assays using purified
recombinant proteins. In the absence of ASPL, p97 hexamers
readily hydrolyzed ATP (Fig. 3f). When ASPL-C was added to p97
hexamers, however, this activity was reduced in a concentration-
dependent manner, indicating that ASPL-mediated hexamer
disassembly is associated with inhibition of ATP hydrolysis. A
dramatically reduced ATPase activity was also observed when
purified p97:ASPL-C heterotetramers were analysed (Fig. 3f).
Finally, we examined whether ASPL-C influences the ATPase
activity of p97 hexamers harbouring the disease-causing mutation
A232E (ref. 36). This mutation was previously shown to
accelerate ATP turnover28, suggesting that hyperactive p97
hexamers are present in IBMPFD patients. In comparison to wt
p97 hexamers, A232E hexamers exhibited an increased ATPase
activity (Fig. 3f), which was significantly diminished in ASPL-C
treated samples, supporting the results with wt p97.
ASPL triggers a reorientation of the D2 ATPase domain in p97.
Examination of the p97-ND1:ASPL-C heterotetramer structure
(Fig. 3a) suggested that the formation of an analogous structure
involving full-length p97 would be prevented by a steric clash
between ASPL-C and the p97 D2 domain unless this domain
adopts a structure that is different from the one observed in pre-
viously described p97 hexamers19. To address this question, we
determined the crystal structure of nearly full-length p97 (residues
2–766) in complex with ASPL-CD (residues 313–500) at a
resolution of 3.4Å (Fig. 4a and Supplementary Table 2).
Protein complex formation was induced by an ASPL-CD
fragment that, compared with ASPL-C, lacks 53 disordered
C-terminal amino acids (Fig. 2b). The asymmetric unit of the
crystal contains one p97:ASPL-CD heterodimeric unit
(Supplementary Movie 2); p97:ASPL-CD heterotetramers were
generated by a crystallographic dyad axis (Fig. 4a).
We found that the overall structures of the p97:ASPL-CD and
p97-ND1:ASPL-C heterotetramers are very similar (r.m.s.d.¼
0.66 Å for the matching a-carbons), indicating that the N and D1
domains in p97 and the eUBX domain in ASPL have similar folds
in both complexes. However, the p97:ASPL-CD complex buries a
larger surface ofB7,000Å2 (Supplementary Movie 3), suggesting
that the D2 domain of p97 also contributes to the assembly of the
heterotetramer (Fig. 4a). Overall, the structure of the D2 domain
in p97:ASPL-CD heterotetramers is very similar to the one
Figure 3 | Structure of the ASPL-C:p97-ND1 heterotetramer. (a) Surface representation of a heterotetrameric p97-ND1:ASPL-C protein complex in two
orthogonal orientations. One heterodimeric unit is displayed in shades of grey, the other is shown in multiple colours, blue (ASPL-C), pink (p97-N)
and wheat (p97-D1). (b) Domain annotation and secondary structure of ASPL-C. The b-grasp fold (bbabbab) of the canonical UBX domain is coloured in
light blue, the extensions b0, a3 and a4 in light grey, and the helical lariat in dark blue. (c) Ribbon-type representation of ASPL-C with colours as in b.
(d) Structure of a single heterodimeric p97-ND1:ASPL-C unit observed within the heterotetramer. ASPL-C (blue) is shown as cartoon underneath a
translucent molecular surface. The Na (salmon colour) and Nb (pink) subdomains and the D1 domain (wheat colour) of p97 are displayed as
cartoon structure. The partially disordered p97 D1-D2 linker is highlighted in black. ADP is depicted as stick model with a bound Mg2þ ion (green).
(e) Coomassie-stained blue-native gel showing the effects of site-directed mutagenesis of conserved ASPL-C residues on the disassembly of p97
hexamers. ASPL-C (3 mg) or its indicated variants were combined with p97 (10mg) and incubated on ice for 5min. Then, samples were analysed by
BN-PAGE. (f) ATPase activities of full-length p97 or its indicated variant in the presence or absence of ASPL-C were determined using a high-performance
liquid chromatography-based assay. Molar ratios between ASPL-C and p97 are indicated. Wild-type (WT) p97 or the mutated protein p97-A232E were
combined with a three-fold molar excess of ASPL-C and briefly incubated on ice. Then, the recombinant proteins were analysed by size-exclusion
chromatography and heterotetrameric protein complexes (p97:ASPL-C or p97-A232E:ASPL-C) were isolated. ATPase activities of interacting recombinant
proteins were analysed by high-performance liquid chromatography. Data are expressed as mean±s.e. (n¼ 3).
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previously described for p97 hexamers19, indicating that ASPL-
CD-mediated remodelling of p97 hexamers does not alter the
conformation of the D2 domain (Supplementary Fig. 7a).
However, we found a different spatial orientation (Fig. 4b and
Supplementary Fig. 7b–d), indicating that binding of ASPL-CD to
p97 triggers a drastic reorientation of the D2 domain. The
movement of the D2 domain involves a 141 rotation around a
hinge located at residue Leu464 in the D1-D2 linker region
(Supplementary Movie 4), indicating that p97:ASPL-CD
heterotetramers (Fig. 4c) expose different surfaces than
previously reported p97 hexamers.
Our structural data also provide an explanation for the reduced
ATPase activity observed with p97:ASPL-C heterotetramers
(Fig. 3f). Interprotomer contacts between D2 domains via arginine
635 are critical for efficient ATP hydrolysis at physiological
temperatures37,38; in p97:ASPL-CD heterotetramers, these contacts
are not observed (Supplementary Fig. 7e).
ASPL causes ERAD impairment and toxicity in mammalian cells.
First, we examined whether overexpression of full-length ASPL can
promote p97 hexamer disassembly in mammalian cells. We over-
produced EGFP-tagged full-length ASPL in HEK293 cells and
examined the formation of p97:ASPL-GFP protein complexes by
BN-PAGE and IB. We found that EGFP-ASPL overproduction
resulted in a concentration-dependent reduction of endogenous
p97 hexamers (B700kDa) and promoted the formation of
p97:ASPL-GFP heterooligomers (B350 kDa) (Fig. 5a and
Supplementary Fig. 8a,b). We further strengthened these findings
by providing additional experimental evidence with size-exclusion
chromatography studies. We confirmed that His-tagged, full-length
ASPL can indeed disassemble preformed p97 hexamers and
converts them into lower molecular weight protein complexes with
a size of B300 kDa in vitro (Supplementary Fig. 8d,e).
Next, we assessed whether the ASPL mutants D351A and
PP437-438AA promote p97 hexamer disassembly in cells. Analysis
by BN-PAGE and IB revealed that the p97 hexamer-disassociation
activity of the EGFP-tagged proteins D351A and PP437-438AA
is significantly decreased in comparison with wt EGFP-ASPL
(Fig. 5b and Supplementary Fig. 8c), supporting the results from
the cell-free assays (Fig. 3e).
We then examined whether ASPL-mediated p97 hexamer
disassembly influences described functions of p97 such as its role
in endoplasmic reticulum-associated protein degradation
(ERAD)39. We used the substrate CFP-CD3d (ref. 40) to
examine the effects of wt and mutant ASPL variants on p97
function in the ERAD pathway. The abundance of CFP-CD3d
was approximately fivefold increased in cells overproducing
wt EGFP-ASPL compared with cells overproducing D351A or
PP437-438AA (Fig. 5c,d), indicating that ASPL-mediated
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perturbation of p97 hexamer function is associated with ERAD
inhibition in mammalian cells.
To substantiate this observation, we also assessed whether the
endogenous levels of other known ERAD proteins are altered in
response to ASPL overproduction. We overproduced the proteins
EGFP-ASPL-WT, EGFP-ASPL-PP437-438AA or EGFP-ASPL-
D351A in HeLa cells and quantified the abundance of newly
synthesized L-azidohomoalanine (AHA)-labelled proteins41 using
SILAC (stable isotope labelling with amino acids in cell culture42)
-based quantitative mass spectrometry (Supplementary Fig. 9a).
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We found that overproduction of EGFP-ASPL-WT elevated the
levels of the known ERAD pathway proteins BiP and Sec63
(Supplementary Fig. 9b), while such an effect was not observed
with the mutated proteins EGFP-ASPL-PP437-438AA or
EGFP-ASPL-D351A, substantiating the hypothesis that
overproduction of wt ASPL perturbs ERAD function. A similar
result was also obtained when the known p97 inhibitor NMS873
(ref. 43) was assessed with SILAC experiments in HeLa cells.
Perturbation of ERAD and p97 ATPase activity were
previously shown to be associated with caspase activation in
mammalian cells44. We therefore investigated in further studies
whether overexpression of ASPL influences the activity of effector
caspases in mammalian cells. We found that overproduction of
wt ASPL in HEK293 cells resulted in an approximately fourfold
increase in caspase-3/7 activity, while such an effect was not
observed with the ASPL mutants D351A and PP437-438AA
(Fig. 5e). This supports previous observations that ERAD
impairment causes proteotoxic stress and activation of caspases45.
Finally, we employed a flow cytometry-based live–dead cell
discrimination assay46 to examine whether EGFP-ASPL
overproduction causes mammalian cell death. We observed a
significant increase of dead cells when wt EGFP-ASPL was
overproduced in HEK293 cells, while such an effect was not
observed with the EGFP-tagged mutant proteins D351A and
PP437-438AA (Fig. 5f). Similar results were also obtained when
full-length wt ASPL or its truncated fragment ASPL-CD were
overproduced in HeLa, HCT116 or U2OS cancer cell lines
(Supplementary Fig. 10a,b).
Uptake of a short ASPL polypeptide decreases cell viability. To
study whether ASPL-derived polypeptides influence cell viability,
we generated purified, recombinant ASPL-CD-EGFP fusion
proteins (wt ASPL-CD and its mutated variants PP437-438AA
and D351A) with and without an N-terminal poly-arginine (R11)
tag (Fig. 5g and Supplementary Fig. 10c) and assessed whether
they are taken up into mammalian cells when added to the
culture medium. Analysis of cells by confocal microscopy showed
that after 4 h of incubation the R11-tagged but not the untagged
ASPL fusion proteins were detectable in HeLa cells (Fig. 5h
and Supplementary Fig. 10d), indicating that the N-terminal
poly-arginine tag promotes the uptake of proteins into cells. Next,
we applied the flow cytometry-based LIVE/DEAD fluorescent
cell-staining assay to investigate whether the uptake of the
R11-ASPL-CD-EGFP fusion proteins into cells influences their
viability. We observed a concentration-dependent increase of
dead cells with the wt ASPL-CD fusion protein but not with the
mutant variants PP437-438AA and D351A (Fig. 5i and
Supplementary Fig. 10e), confirming the results observed in
overexpression experiments (Supplementary Fig. 10a,b).
Discussion
In this study, we applied a two-step interaction mapping
approach including automated Y2H screening and systematic
validation of binary PPIs with a DULIP assay to identify
high-affinity interaction partners for the AAAþ ATPase p97.
p97 is a hexameric molecular machine that carries out diverse
cellular functions in association with partner proteins30. Among
others, p97 was shown to play a critical role in the degradation of
misfolded proteins and to be involved in cellular processes such
as Golgi membrane assembly47 or autophagosome formation16.
Multiple partner and adaptor proteins of p97 have been identified
with a variety of techniques25,48. However, detailed information
on binding affinities or mechanisms is mostly missing. This
information is of particular importance as previous investigations
with p97 interactors indicate that they bind sequentially to
specific domains in p97 (ref. 49), suggesting that high-affinity
binders could displace other proteins from p97 hexamers and
thereby influence their specific cellular functions.
Through our quantitative PPI mapping approach, we were able
to rank the initially identified p97 interaction partners based on
normalized interaction ratios (NIRs), an indicator of interaction
strength13. This analysis revealed that among 14 proteins identified
in Y2H assays, the UBX domain-containing protein ASPL binds
most strongly to p97 (Fig. 1c). The interaction between ASPL and
p97 has been reported previously25,50, information on interaction
strength and whether the association with ASPL is stronger or
weaker than other p97 interactions is unavailable, however.
Evaluating our quantitative interaction data (Fig. 1c), we could
group the identified p97 interaction partners according to their
NIRs and define potential hierarchies among them that might be of
relevance for a better understanding of p97 function.
Previous studies indicate that binding of ASPL or its orthologues
to p97 promotes hexamer disassembly51–53, suggesting that the
protein functions as a regulator of p97 ATPase activity. Our
investigations of the interaction using biochemical and high-
resolution structural methods support this view. Beyond previous
findings, we could demonstrate that a C-terminal ASPL fragment
harbouring an eUBX domain and an a-helical lariat are necessary
and sufficient for the dissociation of p97 hexamers as well as the
inhibition of ATPase activity (Fig. 3). Strikingly, we also found that
ASPL-C-mediated hexamer disassembly causes the formation of
stable p97:ASPL-C heterotetramers with a compact globular
structure in cell-free assays.
This leads to the question of how the C-terminal fragments
ASPL-C or ASPL-CD (Fig. 2b) promote p97 hexamer disassembly.
Our biochemical and structural studies suggest that the eUBX
domain, which contacts the N domain in p97 through a
conserved cis-Pro touch-turn motif, is important for the initial
association with p97 hexamers, while the a-helical lariat structure
is critical for hexamer dissociation (Fig. 3b,c and Supplementary
Figs 5 and 6). Thus, both subdomains of ASPL-C or ASPL-CD
cooperate to target and disassemble p97 hexamers. While the
importance of UBX domains in adaptor proteins for binding p97
hexamers is well documented26,32, an a-helical lariat structure
that promotes hexamer disassembly has not been described
previously. Our structural investigations suggest that the a-helical
lariat in ASPL is a flexible structure that directly targets the
D1:D1 interprotomer interface in p97 hexamers (Supplementary
Fig. 5c), a region crucial for oligomer stability35. This interaction
subsequently promotes the dissociation of p97 hexamers into
ASPL-C-bound protomers, which spontaneously assemble into
stable p97:ASPL-C heterotetramers. Interestingly, our structural
studies revealed that the formation of p97:ASPL-CD
heterotetramers is accompanied by a reorientation of the
D2 ATPase domain (Fig. 4). We suggest that this relocation of
the D2 domain is critical for the assembly of stable p97:ASPL-CD
heterotetramers and the inhibition of ATPase activity (Fig. 3f).
A mechanistic model outlining the potential steps of the
ASPL-C-mediated p97 hexamer disassembly and the
heterotetramer re-assembly process is shown in Fig. 6.
Based on these results, we primarily addressed the question of
whether ASPL-derived fragments can be utilized as specific
inhibitors to perturb p97 hexamer function in cell model systems.
p97 is an essential protein and conserved across all eukaryotes.
Furthermore, it was shown that p97 is involved in the
development of various cancers23. A specific inhibitor of the
protein would be a highly relevant tool to investigate its diverse
functional roles and to evaluate its potential as a therapeutic
target in human disease. We demonstrate that both
overexpression of ASPL and the addition of a cell-permeable
truncated ASPL fragment efficiently induces death of mammalian
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cells (Fig. 5f–i and Supplementary Fig. 10a,b), indicating that
ASPL-derived polypeptides are potent inhibitors of p97 function.
Overproduction of ASPL in cells was associated with inhibition
of ERAD and mobilization of executioner caspases 3 and 7
(Fig. 5c–e), suggesting that high levels of ASPL induce cellular
toxicity through inhibition of p97-dependent protein degradation
pathways. Our investigations are in good agreement with studies
of the small-molecule inhibitors of p97 such as DBeQ and
CB-5083, which were shown to potently inhibit cancer cell
growth, block ERAD and activate executioner caspases43,44,54–56.
Our findings provide a rationale for targeting the N and D1
domains in p97, thereby disrupting the hexamer structure and
inhibiting the ATPase activity of p97. Based on the high-
resolution structures we describe, we envision that highly specific
therapeutic molecules should be designed that directly target p97
hexamers and inhibit their function in cancer cells.
Methods
Production and purification of recombinant proteins. Full-length cDNAs
encoding human ASPL and p97 were obtained from the Mammalian Gene
Collection library. All plasmids were generated using standard PCR-based cloning
strategies; Sanger sequencing verified nucleotide sequences. Human C-terminally
His-tagged full-length ASPL (residues 1–553), ASPL-C (residues 313–553), ASPL-
CD (residues 313–500), R11-ASPL-CD-EGFP (and its variants: PP437-438AA,
D351A), ASPL-CD-EGFP and ASPL-C variants containing the indicated mutations
were produced from pQLinkG57 as N-terminally tagged GST fusions followed by a
TEV (Tobacco Etch Virus) protease cleavage site in the Escherichia coli host strain
BL21 DE3 Rosetta2. Bacteria were grown to an optical density of 1 at 37 C; gene
expression was induced using 1mM isopropyl-b-D-thio-galactopyranoside (IPTG)
and bacteria were grown overnight at 18 C. Cells resuspended in PBS containing
5% glycerol, 1 mM Benzonase (Roche) and a complete, EDTA-free protease
inhibitor cocktail (Merck) were disrupted by brief sonication (UW 2200, Bandelin).
After removal of the cell debris by centrifugation, the supernatant was incubated
with glutathione-Sepharose 4B beads (GE Healthcare). Subsequently, beads were
washed with PBS, and the bound proteins were eluted with PBS containing 30mM
reduced glutathione (Sigma). Eluted proteins were incubated with His6-tagged TEV
protease and dialyzed overnight against buffer A (20mM HEPES/NaOH pH 7.4,
200mM NaCl and 2mM DTT). GST and TEV protease were separated from
ASPL-C using glutathione-Sepharose beads and Ni-NTA resin (Qiagen) followed
by size-exclusion chromatography on a Superdex S200 column (GE Healthcare) in
buffer A. Purified ASPL-C fractions were pooled, concentrated (10,000 MWCO,
Amicon) and flash-frozen in liquid nitrogen.
Human p97 (residues 2–806), nearly full-length p97 (residues 2–766) and
p97-ND1 (residues 1–480) were produced as His6-tagged fusions from pQLinkH
(ref. 57) in E. coli BL21 DE3 Rosetta2, using the conditions described for ASPL-C.
The proteins were purified according to reference19. After affinity purification
using Ni-NTA resin, the proteins were incubated with TEV protease and dialyzed
against buffer A overnight, followed by size-exclusion chromatography on a
Superdex S200 column (GE Healthcare) in buffer A. Purified p97 fractions were
pooled, concentrated using ultrafiltration (30,000 molecular weight cutoff; Amicon)
and flash-frozen in liquid nitrogen. Purified p97 protein was examined for the
presence of bound nucleotides using reverse-phase chromatography (Hypersil
ODS-2 C18 column). All biochemical experiments were performed with full-length
p97 (residues 2–806).
Crystallization and structure determination. Purified p97-ND1 (residues 1–480)
was pre-incubated with 2mM ADP and 5mMMgCl2 for 1 h at 4 C and mixed with
purified ASPL-C (residues 313–553) in a 1:3 molar ratio. The reconstituted protein
complexes were subjected to size-exclusion chromatography on a Superdex S200
column (GE Healthcare) in buffer A supplemented with 2mM ADP and 5mM
MgCl2. The purified p97-ND1:ASPL-C protein complex was concentrated and
supplemented with 15mM KCl (300nl at a concentration of 12.3mgml 1) and
mixed with an equal volume of reservoir solution containing 23% PEG 3350, 0.3M
Li2SO4, 0.1M HEPES/NaOH (pH 7.0). p97:ASPL-CD protein complexes were pre-
pared as described above for the p97-ND1:ASPL-C complex. The crystallization
experiments were performed using the sitting-drop vapour-diffusion method at 4 C
with a Gryphon pipetting robot (Matrix Technologies Corporation) and a Rock
Imager 1000 storage system (Formulatrix). Crystals of the p97:ASPL-CD complex
(300 nl at a concentration of 15.5mgml 1) were obtained by mixing an equal
volume (200nl) of reservoir solution (2M ammonium sulfate, 0.1M Bis-Tris pH 5.5)
with the protein solution. Crystals of both complexes appeared after 2 weeks and
were flash-frozen in liquid nitrogen in a cryo solution containing additionally 20%
glycerol relative to the reservoir solution. All data were recorded at BL14.1 at BESSY
II (Helmholtz-Zentrum Berlin, HZB) at a wavelength of 0.9184Å, processed and
scaled using the XDS suite58. Phases for the p97-ND1:ASPL-C complex were
obtained by molecular replacement with Phaser59 using the p97-ND1 domain (PDB
code 1S3S) as a search model. For p97:ASPL-CD, the fully refined p97-ND1:ASPL-C
complex structure was used for molecular replacement. Both protein complex
structures were manually built using COOT60 and iteratively refined using Phenix61
and Refmac62. The final p97-ND1:ASPL-C structure comprises amino acids 313–495
for ASPL-C and 21–480 for p97-ND1. Residues 313–316, 468–470 and 498–553 for
ASPL-C and residues 1–20, 428–432 and 462–472 for p97-ND1 were disordered and
therefore not visible in the electron density. The p97:ASPL-CD complex consists of
residues 317–499 for ASPL-CD and 13–761 for p97. Unstructured regions were
found for residues 313–316 in ASPL-CD and residues 2–12, 427–433, 495–510,
585–596, 613–615 and 762–766 in p97. In the p97-ND1:ASPL-C complex, 99.8% of
the residues were in the allowed regions of the Ramachandran map. In the
p97:ASPL-CD structure 100% of all residues were in the allowed regions of the
Ramachandran map. The Ramachandran statistics were analysed by Molprobity63
for both complexes. Figures and domain superpositions were generated with PyMol
(http://www.pymol.org). The Dali server64 was used to search for structural
homologues of ASPL. The analysis of the p97:ASPL interface was performed with
PISA65. The rearrangement of the p97 D2 domain was determined as a hinge-like
141 rotation centred at Leu464 coupled to a 3Å translation along the rotation axis
by DynDom66. The movies S1–4 were generated by using the program Pymol.
The simulation of the D2 domain rearrangement was generated by using the morph
server67.
Co-immunoprecipitations. Human brain extracts were prepared from B4 g of
brain and homogenized briefly in ice-cold PBS supplemented with 1% Triton
X-100, complete protease inhibitor cocktail (Roche) and Benzonase (Merck).
The homogenate was subjected to centrifugation at 20,000g for 10min at 4 C; the
supernatant was collected and used for co-immunoprecipitation experiments as
described previously with indicated modifications68. Magnetic beads coupled with
protein G (Dynabeads; Invitrogen) were incubated with anti-ASPL antibody
(Abnova, clone 3D10-1D11,1:500 dilution) for 1 h at 4 C. Antibody bound to
magnetic beads was crosslinked using 5mM BS (ref. 3) (Thermo Scientific)
according to the manufacturer’s instructions. Magnetic beads with crosslinked
antibody were incubated with human brain homogenate at 4 C with rotation for
1 h. The bound protein complexes were washed briefly with PBS containing 1%
D2
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p97: ASPL-C heterodimerp97: ASPL-C heterotetramer
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D
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Figure 6 | Structure-based model for the disassembly of p97 hexamers
through the interaction with ASPL-C. ASPL-C-mediated disassembly of
p97 hexamers is a multistep process. In the first step, ASPL-C docks onto
the p97 surface via its cis-Pro touch-turn motif that is conserved in the
eUBX domain. Next, the ASPL-C helical lariat disrupts the association of
p97 protomers by targeting the D1 ring and binding to the p97 Na
subdomain. This results in the generation of six metastable p97:ASPL-C
heterodimer units, which rapidly re-assemble into stable heterotetramers.
Concomitantly, the D2 domain in p97 undergoes a B140 rotation from a
closed to an open conformation, preventing the re-association of protomers
into p97 hexamers.
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Triton X-100, followed by elution of protein complexes with SDS sample buffer.
Proteins were analysed by SDS–PAGE and western blotting using anti-ASPL
(Abnova clone 3D10-1D11, 1:500 dilution) and anti-p97 (PROGEN, clone 58.13.3,
1:20,000 dilution) antibodies. Co-IP experiments in reverse direction were carried
out using the Pierce Crosslink Immunoprecipitation Kit (cat. 26147) according to
manufactures instructions using the anti-p97 antibody (LifeSpan Biosciences, cat.
LS-C287469, 1:2,000 dilution).
Recombinant V5-tagged ASPL proteins were overproduced in human
embryonic kidney cells 293 (HEK293). After 48 h media was aspirated and cells
were washed briefly in PBS, lysed using a buffer containing 0.1% NP40, 20mM
HEPES/NaOH pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM EDTA and freshly
supplemented with complete protease inhibitor cocktail (Roche), Benzonase
nuclease (Merck). Lysis was carried out for 30min on ice. The homogenate was
briefly centrifuged on a table top centrifuge for 1–2min to remove the cell debris
and the clarified supernatant was incubated with V5-agarose beads (Abcam, cat.
ab1229) for 1 h at 4 C with rotation. The bound protein complexes were washed
three times using a buffer containing 0.1% NP40, 20mM HEPES/NaOH pH 7.4,
150mM NaCl, 1.5mM MgCl2 and 1mM EDTA. This was followed by elution of
the protein complexes with elution buffer containing primary amine pH 2.8 from
Pierce Crosslink Immunoprecipitation Kit (cat. 26147). Proteins were analysed by
SDS–PAGE and western blotting using anti-V5 (Abcam, cat. ab27671, 1:1000
dilution), anti-p97 (PROGEN, clone 58.13.3, 1:20,000 dilution) and b-actin
(Sigma- Aldrich, cat. A5441, 1:40,000) antibodies.
DULIP assay. Fusion proteins containing a protein A (PA)-renilla luciferase (RL)
tag were co-produced together with V5-firefly luciferase (FL)-tagged proteins in
HEK293 cells. After 48 h, cells were harvested, lysed in buffer B (0.1% NP40, 50mM
HEPES/NaOH pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM EDTA, 1mM DTT)
containing the Complete protease inhibitor cocktail (Roche) and Benzonase (Merck).
Luciferase activity in protein extracts was measured to monitor the production of
fusion proteins. Protein complexes were captured using IgG (Jackson Immunor-
esearch) immobilized to high-binding 96-well white plates (Greiner). Bound protein
complexes were washed briefly with buffer B lacking NP40, and binding of the
firefly-V5-tagged fusion protein (Co-IP) to the PA-Renilla-tagged fusion protein was
quantified by measuring the firefly luciferase activity in a luminescence plate reader
(TECAN Infinite M200). Renilla-luciferase activity was also measured as a control
(IP). Luciferase activity was measured using the Dual-Glo Luciferase Assay System
(Promega) following the manufacturer’s instructions. Individual PPIs were tested as
triplicates; experiments were repeated at least three times.
Blue native-PAGE. Proteins were analysed by BN-PAGE according to the
manufacturer’s instructions (Invitrogen). Protein samples were resolved on 4–16%
Bis-Tris BN-PAGE gels at 200V at room temperature and visualized by Coomassie
Brilliant Blue staining. The molar concentration of p97 was calculated in terms of
its monomer for all the in vitro experiments (Supplementary Fig. 11). The intensity
of the protein bands was quantified using the Aida image analyser software. Native
p97-containing protein complexes from HEK293 cell extracts were resolved by
BN-PAGE and analysed by western blotting using an anti-p97 antibody
(PROGEN, clone 58.13.3, 1:20,000 dilution) (Supplementary Fig. 11). Western
blotting of BN gels was performed according to the manufacturer’s instructions.
Negative-stain electron microscopy. An amount of 3.5 ml of purified p97
hexamers (residues 2–806) or p97:ASPL-C heterotetramers at a protein
concentration of 10–20 ng ml 1 in buffer A (see Production and purification of
recombinant proteins) were applied to freshly glow-discharged holey carbon grids
(300 mesh R2/4 Quantifoil grids, Quantifoil Micro Tools GmbH, Jena, Germany)
covered with an additional thin layer of continuous carbon and negatively stained
with 2% (w/v) uranyl acetate. Samples were evaluated at 28,500-fold nominal
magnification using a Philips CM100 electron microscope operated at 100 kV,
which was equipped with a 1 k 1 k F114 Fastscan CCD camera (TVIPS).
ATPase assay. ATPase activities of 0.5 mM p97 in the presence and absence of
ASPL-C were determined at 37 C in ATPase buffer containing 20mM HEPES/
NaOH (pH 7.4), 40mM NaCl, 10mM MgCl2. Reactions were initiated by the
addition of 250 mM ATP to samples. At different time points, reaction aliquots
were taken, diluted 15-fold in ATPase buffer and quickly transferred to liquid
nitrogen. Nucleotides in these samples were separated by a reversed-phase Hypersil
ODS-2 C18 column (250 4mm) with 10mM tetrabutylammonium bromide,
100mM potassium phosphate (pH 6.5), 7.5% acetonitrile as running buffer.
Denatured proteins were adsorbed at a C18 guard column. Nucleotides
were detected by absorption at 254 nm and quantified by integration of the
corresponding peaks. Rates were derived from a linear fit to the initial reaction.
Caspase 3/7 assays. HEK293 cells were grown at 37 C and 5% CO2 in
Dulbecco’s modified Eagle medium (DMEM) supplemented with 1 g l 1 D-glucose,
10% fetal calf serum (FCS), penicillin (100 mgml 1) and streptomycin
(100 mgml 1). Equal numbers of HEK293 cells were seeded on a 96-well
microtiter plate. After 24 h, cells were transfected with pEGFP-C1 (Clontech)
fusion constructs encoding ASPL or indicated ASPL variants using PEI
(polyethyleneimine, Polysciences) for 72 h. The activation of caspases 3/7 was
monitored using the Apo-ONE Homogeneous Caspase-3/7 Assay kit (Promega).
The caspase-3/7 substrate added to each well was mixed briefly by shaking and
incubated for 1 h at room temperature. The fluorescence signal was determined
using a plate reader (TECAN Infinite M200). The expression of ASPL constructs
and p97 was monitored by IB using anti-GFP (Abgent, cat. AM1009a,1:10,000
dilution) and anti-p97 (PROGEN, clone 58.13.3, 1:20,000 dilution) antibodies,
respectively. The expression of b-actin was also monitored by IB using an anti-b
actin antibody (Sigma-Aldrich, cat. A5441, 1:40,000).
ERAD assay. CFP-tagged T-cell receptor subunit CD3d, an ERAD model
substrate, was co-expressed with EGFP-ASPL in HEK293 cells. After 24 h, cell
lysates were prepared and the steady-state levels of CFP-CD3d were analysed by
SDS–PAGE and IB using an anti-CD3d antibody (Santa Cruz, cat. SC-137137,
1:500) (Supplementary Fig. 11). The expression of ASPL constructs and p97 was
monitored by IB using anti-GFP (Abgent, cat. AM1009a) and anti-p97 (PROGEN,
clone 58.13.3, 1:20,000 dilution) antibodies, respectively. The expression of b-actin
was also monitored by IB using an anti-b-actin antibody (Sigma-Aldrich, cat.
A5441, 1:40,000).
LIVE/DEAD assay. HEK293, HeLa (human cervical cancer cells), U20S
(human osteosarcoma cells) and HCT116 (human colon carcinoma cells) cell lines
were grown at 37 C and 5% CO2 in DMEM supplemented with either 1 g l 1
D-glucose (HEK293, HeLa, U20S) or 4 g l 1 D-glucose (HCT116), 10% fetal calf
serum, penicillin (100 mgml 1) and streptomycin (100 mgml 1). The LIVE/
DEAD fixable far-red cell stain (Life Technologies) was used to discriminate live
and dead cells according to the manufacturer’s instructions. Briefly, 1 106 cells
were harvested, washed and treated with either the indicated ASPL-CD recombi-
nant proteins for 24 h or transfected with pEGFP-C1 (Clontech) fusion constructs
encoding ASPL or indicated ASPL variants using PEI (polyethyleneimine,
Polysciences) for 72 h. Cells were harvested and 1 ml of dye was added to each
sample, mixed, and then incubated in the dark for 30min at room temperature,
washed and fixed in 2% formaldehyde in PBS for 15min. Fixed cells were
maintained in 300ml PBS with 1% FCS at 4 C in the dark until flow-cytometry
analysis was started. All stained cells were analysed on a BD FACSCanto
(BD Biosciences) flow cytometer. Cell death was always analysed in 10,000
EGFP-positive cells per sample using the FlowJo flow cytometry analysis software.
Detection and identification of newly synthesized proteins. HeLa cells were
grown at 37 C and 5% CO2 in SILAC DMEM. SILAC media were essentially
prepared as described previously42. Briefly, we used DMEM Glutamax lacking
arginine and lysine (custom preparation from Gibco) supplemented with 10%
dialyzed fetal bovine serum (dFBS, Gibco) for all experiments. To prepare ‘heavy’
(H) or ‘medium’ (M) SILAC media we added the following isotopically labelled
amino acids: heavy, 13C615N4 L-arginine and 13C615N2 L-lysine; Medium, 13C6
L-arginine and 2H4 L-lysine. Labelled amino acids were purchased from Cambridge
Isotope Laboratories. ‘Light’ (L) SILAC medium was prepared by adding the
corresponding non-labelled amino acids (Sigma).
Transient transfections of cells with plasmids were performed using linear
polyethylenimine (Sigma). Twenty-four hours after transfection cells were washed
thrice with pre-warmed PBS; then they were further cultivated for an hour in an
appropriate cell culture medium lacking methionine. After 1 h cells were treated
with 1mM AHA (L-aziodohomoalanine, Anaspec) and grown for 4 h. The cells
were trypsinized and collected for subsequent analysis.
Cells were lyzed according to the ‘Click-iT Enrichment Kit’ protocol
(Invitrogen) with minor modifications, as previously described69. In short, cells
were incubated in Urea lysis buffer supplemented with complete protease
inhibitors (Roche) and nuclease (Benzonase, Merck) on ice. Samples were spun
down at 13,000g and supernatants were transferred to fresh Eppendorf tubes.
Lysates were mixed 1:1:1 always with a EGFP control in either ‘light’ or ‘heavy’
present as a spike in. The spike was added so that all samples could be compared
between the mass spec runs. Click reactions between newly synthesized azide-
bearing proteins and alkyne-agarose beads were performed overnight following the
kit instructions. Reduction of proteins by denaturation at 70 C in the presence of
10mM DTT was followed by alkylation of sulphydryl groups with 40mM
iodoacetamide were all executed according to the kit protocol. The alkyne beads
were then stringently washed sequentially in SDS buffer, 8M urea in 100mM Tris
(pH 8) and finally 80% acetonitrile by vortexing in buffer followed by
centrifugation of beads and decanting of supernatant. AHA-containing proteins
covalently linked to the alkyne beads were digested by LysC in 50mM ammonium
bicarbonate buffer with 5% acetonitrile for three hours and then by trypsin
overnight. Resulting peptides were stored in StageTips70.
Peptides were eluted from StageTips by 80% acetonitrile and 0.1% formic acid and
followed by evaporation of organic solvent. Peptides were resuspended in 5%
acetonitrile and 3% trifluoroacetic acid and in this buffer loaded onto a 15-cm-long
column with an inner diameter of 75mm filled with ReproSil-Pur 120 C18-AQ 3mm
resin (Dr Maisch GmbH). Peptides were eluted from the column using a high-
performance liquid chromatography system (ThermoScientific) by a four-hour
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gradient of increasing concentration of acetonitrile with a flow rate of 250nlmin 1.
Eluted peptides were ionized by a heated electrospray ionization source (Thermo-
Scientific) and analysed on a Q Exactive mass spectrometer (ThermoScientific). Ions
in the MS-full scans were analysed in the orbitrap at a resolution of 70,000 after
collecting 3,000,000 ions or after the maximum collection time of 20ms. A
data-dependent mode was used and the top 10 most intense ions in the full scan were
selected for fragmentation in the higher-energy collision-induced dissociation cell.
The resulting ion fragments were analysed in the orbitrap at a resolution of 17,500
after collecting 1,000,000 ions or a maximum collection time of 60ms.
Raw files were processed using the MaxQuant software version 1.5.2.8 (ref. 71)
with default settings except ‘match-between runs’ which was activated. Arg10 and
Lys8 were set as labels, carbamidomethyl of C-termini was set as fixed modification
and N-terminal acetylation, deamidation of aspargine and glutamine and oxidation
of methionine were set as variable modifications. The Andromeda search engine
matched the acquired MS/MS spectra against an in silico trypsin/P digested human
Uniprot data base (2014-01). False discovery rates were set to 1% both at peptide
and protein levels and were assessed by in parallel searching against a reversed
version of the database. Graphs and statistics were performed using R version
2.15.1 (R Foundation for Statistical Computing, Vienna, Austria).
Protein transduction and confocal microscopy. Protein transduction was carried
out as described previously with indicated modifications. Briefly, 4 105 HeLa cells
were plated onto glass-bottom dishes (Mattek) and on the next day cells were
washed thrice with DMEM (Gibco). Flashed frozen recombinant proteins were
thawed and briefly centrifuged at 20,000g on table top centrifuge at 4 C. Cells were
treated with recombinant proteins (25, 75 and 100 nM) in 800 ml of DMEM; after
4–5 h DMEM with 20% FCS containing penicillin (100 mgml 1) and streptomycin
(100 mgml 1) was added to cells and they were incubated overnight. Next, live and
dead cells were quantified in the EGFP-positive cell populations. Cellular uptake of
recombinant proteins was monitored using confocal imaging microscopy. Cells
were treated with 100 nM of recombinant proteins for 4 h, cells were washed with
PBS, fixed with 4% formaldehyde. The cells were imaged using an Olympus
Fluoview 1000 confocal laser scanning microscopy with a  60/1.3 NA silicon oil
lens. Images were acquired with a z-step size of 0.2 mm, a pinhole of 0.9 AU and
line averaging of 48. The images were analysed using Fiji software.
Static light scattering. A coupled RALS (Right-Angle Light Scattering)-refractive
index detector (Malvern) was connected in-line to an analytical gel-filtration
column Superdex S200 10/300 to determine absolute molecular masses of eluted
proteins. Data were analysed with the provided software. The running buffer
contained 20mM HEPES (pH 7.5), 200mM NaCl, 2mM MgCl2 and 2mM DTT.
For each protein sample, 100 ml of a 3mgml 1 solution was applied.
Isothermal titration calorimetry (ITC). ITC experiments were performed using a
VP-ITC titration microcalorimeter (GE Healthcare, Freiburg, Germany). All
titrations were performed in a buffer containing 20mM HEPES/NaOH pH 7.4,
200mM NaCl, 5mM MgCl2, 2mM ADP at 25 C. 80 mM of ASPL-C were titrated
into 8 mM p97-ND1. Raw data in the form of incremental heat per mole of added
ligand for the titration were fitted by nonlinear least squares with the ORIGIN7
software using a one-site binding model.
Biolayer interferometry (BLI). The binding kinetics of p97 with ASPL-His were
measured by BLI using a single-channel BLItz instrument (Pall, forte´Bio). 1 mM
ASPL-His (20mM HEPES/NaOH pH 7.4, 200mM NaCl, 1mgml 1 BSA) was
captured on HIS2 biosensors (Pall, forte´Bio) for 400 s, and the biosensors were
subsequently washed for 600 s in buffer (20mM HEPES/NaOH pH 7.4, 200mM
NaCl). Subsequently, the kinetics were measured, beginning with a 60 s baseline,
200 s association phase with varying concentrations of p97 (20mM HEPES/NaOH
pH 7.4, 200mM NaCl, 100 nM to 12.5 nM), and a 200 s dissociation phase in
buffer. Negative control experiments with the HIS2 biosensor without ASPL-His
against the maximally used concentration of p97 (100 nM) were carried out.
Conversely, HIS2 biosensor loaded with ASPL-His against buffer control
(20mM HEPES/NaOH pH 7.4, 200mM NaCl) were also carried out. All
measurements were done at room temperature. The data were analysed using the
programming language R using a 1:1 binding model.
Data availability. The atomic coordinates of p97-ND1:ASPL-C and p97:ASPL-CD
have been deposited in the Protein Data Bank with accession codes 5IFS and 5IFW,
respectively. All other data relevant to this work are available from the authors on
reasonable request.
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